Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

Lexicon Pharmaceuticals (LXRX) jumped nearly 6% after Cantor Fitzgerald analyst Steve Seedhouse initiated coverage with an overweight rating and an $8 price target. At the current price of $1.90, Seedhouse's target implies more than 4x upside.

The bullish call centers on sotagliflozin, an FDA-approved heart failure treatment that LXRX is now developing for hypertrophic cardiomyopathy. Seedhouse noted the drug operates through a different mechanism than competing therapies in the space, potentially offering a differentiated treatment option.

The $8 target represents a significant re-rating for LXRX shares, which have traded under pressure. Cantor's initiation signals institutional confidence in the drug's commercial potential beyond its current heart failure indication.